Development of a 177Lu-Labeled Glypican-3-Targeted Antibody Radiopharmaceutical for Adjuvant Radionuclide Therapy Following Hepatocellular Carcinoma Resection
{{output}}
Background: Hepatocellular carcinoma (HCC) remains the major cause of cancer-related mortality worldwide due to high postoperative recurrence rates and limited treatment options for minimal residual disease (MRD).Methods: In this study, glypican-3 (GPC3)-targe... ...
